相关实验视频

Updated: Sep 10, 2025

Mapping Alzheimer's Disease Variants to Their Target Genes Using Computational Analysis of Chromatin Configuration

Mapping Alzheimer's Disease Variants to Their Target Genes Using Computational Analysis of Chromatin Configuration

Published on: January 9, 2020

利用功能性注释来绘制与阿尔茨海默病相关的罕见变体

Anjali Das¹, Chirag Lakhani², Chloé Terwagne³

¹Computer Science, Columbia University, New York, NY, USA; New York Genome Center, New York, NY, USA.

American journal of human genetics

|August 21, 2025

概括

我们开发了一个新的框架, gruyere, 分析复杂疾病的罕见遗传变异. 它通过整合功能注释和细胞类型特定数据来改善阿尔茨海默病 (AD) 风险基因的识别.

科学领域:

基因组学
计算生物学
神经科学

背景情况:

全基因组测序 (WGS) 能够研究复杂疾病中的罕见变异.
现有的VR关联测试往往没有充分利用功能注释数据.
微细胞调节的干扰与阿尔茨海默病 (AD) 风险有关,因此需要对非编码RV进行调查.

研究的目的:

介绍Gruyere,一个经验性的贝叶斯框架,用于全基因组的罕见变异丰富评估.
利用功能性注释和特定细胞类型的数据来改善阿尔茨海默氏症等复杂疾病的变异优先级.
使用微细胞特异性调节区域识别与AD相关的基因和功能性非编码RV.

主要方法:

开发了一个实证贝叶斯框架,用于学习功能注释的特征特定权重.
使用大脑细胞类型中预测的增强剂/促进剂区域,定义了每基因的非编码RV测试集.
纳入细胞类型特定变异效应预测 (VEP) 作为 gruyere 框架内的功能注释.

主要成果:

在阿尔茨海默氏病测序项目WGS数据中应用了Gruyere,确定了13个重要的遗传关联.
在综合测试中仍有四个新的关联,突出显示了格鲁耶的力量.
对于拼接,转录因子结合和染色质状态的深度学习VEP被证明是功能性非编码RV的高度预测.

结论:

格鲁耶为包含多种遗传和功能数据的全基因组关联测试提供了强大的框架.
该框架成功发现了新的AD相关基因和功能注释,包括细胞类型特定的非编码RV.
这种方法通过整合编码和非编码变体信息来增强对复杂疾病遗传学的理解.

关键词:

阿尔茨海默病贝叶斯概率模型功能性注释没有编码的变化罕见的变种全基因组测序

更多相关视频

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease

Published on: April 4, 2018

Author Spotlight: Exploring Sex-Specific Glial Signatures and Therapeutic Leads for Alzheimer's Disease

Author Spotlight: Exploring Sex-Specific Glial Signatures and Therapeutic Leads for Alzheimer's Disease

Published on: May 20, 2024

相关概念视频

Alzheimer's Disease: Overview

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...

Genome-wide Association Studies-GWAS

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...